/DISREGARD RELEASE: NeuroGen/

We are advised by NeuroGen that journalists and other readers should disregard the news release, China’s First CGRP Targeted Therapy to Enter the NRDL: NeuroGen Officially Launches Ajovy® (fremanezumab), Benefiting the First Cohort of Migraine Patients, issued 18-Nov-2026 over PR Newswire. The release has been withdrawn following a change to the issuer’s distribution arrangements.


This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News.


Read the original article : /DISREGARD RELEASE: NeuroGen/

Related Posts

Welcome Back!

Login to your account below

Retrieve your password

Please enter your username or email address to reset your password.

Add New Playlist